Iron chelation in the transfusion-dependent anaemias management is essential to prevent end-organ damage and to improve survival. Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity. Therapeutic drug monitoring is an important tool for optimizing drug utilization and doses.
Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients
ALLEGRA, SARAHFirst
;CUSATO, JESSICA;DE FRANCIA, SILVIA;PIRRO, Elisa;MASSANO, DAVIDE;PIGA, Antonio GiulioCo-last
;D'AVOLIO, ANTONIO
Co-last
2017-01-01
Abstract
Iron chelation in the transfusion-dependent anaemias management is essential to prevent end-organ damage and to improve survival. Deferasirox is a once-daily orally active tridentate selective iron chelator which pharmacokinetic disposition could influence treatment efficacy and toxicity. Therapeutic drug monitoring is an important tool for optimizing drug utilization and doses.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Allegra_et_al-2017-Journal_of_Pharmacy_and_Pharmacology.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
240.67 kB
Formato
Adobe PDF
|
240.67 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
